Pharma IP Alert: Recent P-IV Filings for Spinraza & Austedo XR + Delhi HC’s ₹152 Cr Damages Precedent
Introduction The pharmaceutical landscape is rapidly evolving with strategic P-IV challenges and complex generic developments. Our latest newsletter explores critical updates from the FDA website (as of April 13, 2026) and a significant Delhi High Court judgment that could set a precedent for future pharmaceutical infringement damages in India. Recent Paragraph IV (P-IV) Filings: Strategic Market Entries Generic manufacturers are increasingly targeting high-value orphan drugs and complex formulations to bypass long-term patent barriers. 1. Nusinersen (Spinraza) - Complex Generic Challenge Drug Profile: An antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA). The Opportunity: While 2023 US sales were approximately $500 million, the innovator recently secured a new high-dose regimen approval on March 30, 2026, to shift the patient base before the 12 mg version goes generic. Key Players: Industry analysis suggests potential involvement from Indian firms like Natco and Cipla. ...
